Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A SADOW

Allopathic & Osteopathic Physicians Radiology Body Imaging

NPI
1891772588
CMS profile
176949
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$315,440.00

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $315,440.00 116

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $181,200.00 39
Merck Sharp & Dohme Corporation $134,040.00 75
SANOFI US SERVICES INC. $200.00 2

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A SADOW

NPI 1891772588 · CMS profile ID 176949

Allopathic & Osteopathic Physicians / Radiology / Body Imaging

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891772588?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A SADOW, NPI 1891772588, CMS profile ID 176949. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891772588?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHERYL A SADOW, NPI 1891772588, CMS profile ID 176949. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891772588?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHERYL A SADOW, NPI 1891772588, CMS profile ID 176949, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1891772588?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $315,440.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $315.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848571987 CMS
Merck Sharp & Dohme Corporation $150.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848658445 CMS
Merck Sharp & Dohme Corporation $150.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848698673 CMS
Merck Sharp & Dohme LLC $1,600.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309691 CMS
PFIZER INC. $6,600.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833191805 CMS
PFIZER INC. $560.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833194717 CMS
PFIZER INC. $4,080.0009/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833268271 CMS
Merck Sharp & Dohme Corporation $1,750.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309027 CMS
Merck Sharp & Dohme Corporation $860.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309039 CMS
Merck Sharp & Dohme Corporation $230.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848479697 CMS
Merck Sharp & Dohme Corporation $150.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848489525 CMS
Merck Sharp & Dohme Corporation $140.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848609117 CMS
Merck Sharp & Dohme Corporation $18,800.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848679645 CMS
PFIZER INC. $6,710.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833094665 CMS
PFIZER INC. $10,050.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833191769 CMS
PFIZER INC. $910.0007/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833195209 CMS
Merck Sharp & Dohme Corporation $1,320.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309019 CMS
Merck Sharp & Dohme Corporation $245.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309029 CMS
Merck Sharp & Dohme Corporation $5,600.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848309037 CMS
Merck Sharp & Dohme Corporation $975.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848489527 CMS
Merck Sharp & Dohme Corporation $2,010.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848509551 CMS
Merck Sharp & Dohme Corporation $200.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848530569 CMS
Merck Sharp & Dohme Corporation $4,550.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848530571 CMS
Merck Sharp & Dohme Corporation $280.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848713153 CMS
PFIZER INC. $9,150.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833094655 CMS
PFIZER INC. $3,000.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833191897 CMS
PFIZER INC. $590.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833194947 CMS
SANOFI US SERVICES INC. $100.0006/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843604587 CMS
Merck Sharp & Dohme Corporation $1,650.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848307775 CMS
Merck Sharp & Dohme Corporation $200.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848307891 CMS
Merck Sharp & Dohme Corporation $8,175.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848545629 CMS
Merck Sharp & Dohme Corporation $2,360.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848586147 CMS
Merck Sharp & Dohme Corporation $75.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848628147 CMS
PFIZER INC. $4,250.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833094453 CMS
PFIZER INC. $7,800.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833191699 CMS
PFIZER INC. $1,780.0005/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833194959 CMS
Merck Sharp & Dohme Corporation $140.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848307773 CMS
Merck Sharp & Dohme Corporation $90.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848307895 CMS
Merck Sharp & Dohme Corporation $1,060.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848508981 CMS
Merck Sharp & Dohme Corporation $1,800.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848723543 CMS
Merck Sharp & Dohme Corporation $240.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848723669 CMS
PFIZER INC. $270.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833094009 CMS
PFIZER INC. $15,180.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833094447 CMS
PFIZER INC. $8,200.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833191773 CMS
PFIZER INC. $650.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833195213 CMS
SANOFI US SERVICES INC. $100.0004/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843604585 CMS
Merck Sharp & Dohme Corporation $1,495.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848308477 CMS
Merck Sharp & Dohme Corporation $3,320.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848308479 CMS
Merck Sharp & Dohme Corporation $245.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848444347 CMS
Merck Sharp & Dohme Corporation $1,200.0003/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848545839 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $579,880.00 174
PY2020 $563,150.00 178
PY2021 $315,440.00 116
PY2022 $82,580.00 12
PY2023 $52,745.00 13
PY2024 $39,190.00 13
PY2025 $28,595.00 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $87,510.00 33
PY2024 Principal investigator $135,864.23 58
PY2023 Principal investigator $139,490.61 80
PY2022 Principal investigator $205,452.02 76
PY2021 Principal investigator $794,745.36 166
PY2020 Principal investigator $659,149.58 141
PY2019 Recipient $3,605.00 2
PY2019 Principal investigator $649,746.68 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines Ltd. $120.00 11/25/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344737
Principal investigator 1 Geron Corporation $1,350.00 11/25/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896907
Principal investigator 1 ABBVIE INC. $255.00 10/21/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202517459
Principal investigator 1 BeOne Medicines Ltd. $510.00 10/21/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344733
Principal investigator 1 Geron Corporation $1,425.00 10/21/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896309
Principal investigator 1 ABBVIE INC. $510.00 09/23/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202511846
Principal investigator 1 ABBVIE INC. $1,600.00 09/23/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer No dispute reported 06/30/2026 1202511848
Principal investigator 1 BeOne Medicines Ltd. $1,350.00 09/23/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190344803
Principal investigator 1 Geron Corporation $1,200.00 09/23/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238896060
Principal investigator 1 ABBVIE INC. $680.00 08/26/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202505763
Principal investigator 1 BeOne Medicines Ltd. $1,080.00 08/26/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190344796
Principal investigator 1 Geron Corporation $1,800.00 08/26/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895924
Principal investigator 1 ABBVIE INC. $255.00 07/22/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202499116
Principal investigator 1 BeOne Medicines Ltd. $3,390.00 07/22/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190344800
Principal investigator 1 Geron Corporation $1,650.00 07/22/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895660
Principal investigator 1 ABBVIE INC. $425.00 06/17/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202491783
Principal investigator 1 BeOne Medicines Ltd. $1,920.00 06/17/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190331755
Principal investigator 1 Geron Corporation $1,275.00 06/17/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895366
Principal investigator 1 ABBVIE INC. $340.00 05/20/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202485475
Principal investigator 1 AstraZeneca UK Limited $130.00 05/20/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185537633
Principal investigator 1 BeiGene, Ltd. $1,800.00 05/20/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190321170
Principal investigator 1 Geron Corporation $1,200.00 05/20/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238895219
Principal investigator 1 ABBVIE INC. $340.00 04/22/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202478229
Principal investigator 1 BeiGene, Ltd. $750.00 04/22/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 1190321172
Principal investigator 1 Geron Corporation $1,200.00 04/22/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor No dispute reported 06/30/2026 1238894414
Principal investigator 1 ABBVIE INC. $450.00 03/27/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No dispute reported 06/30/2026 1202466497
Principal investigator 1 ABBVIE INC. $300.00 03/27/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202466500
Principal investigator 1 ABBVIE INC. $340.00 03/27/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202466505
Principal investigator 1 BeiGene, Ltd. $1,680.00 03/27/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323242
Principal investigator 1 BeiGene, Ltd. $1,650.00 02/18/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323244
Principal investigator 1 ABBVIE INC. $595.00 01/21/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202440343
Principal investigator 1 AstraZeneca UK Limited $51,650.00 01/21/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185537635
Principal investigator 1 BeiGene, Ltd. $4,290.00 01/21/2025 Non-covered Recipient Entity
PERITUS IMAGING INC
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell Malignancies No dispute reported 06/30/2026 1190323240